Loading
PPP1R15A (Protein phosphatase 1 regulatory subunit 15A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.
Recruits the serine/threonine-protein phosphatase PPP1CA to prevents excessive phosphorylation of the translation initiation factor eIF-2A/EIF2S1, thereby reversing the shut-off of protein synthesis initiated by stress-inducible kinases and facilitating recovery of cells from stress. Down-regulates the TGF-beta signalling pathway by promoting dephosphorylation of TGFB1 by PP1. May promote apoptosis by inducing p53/TP53 phosphorylation on 'Ser-15'.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Bevacizumab and FOLFIRI Regimen.
In plain words · PPP1R15A (Protein phosphatase 1 regulatory subunit 15A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.
PPP1R15A (Protein phosphatase 1 regulatory subunit 15A) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Colorectal cancer.
Recruits the serine/threonine-protein phosphatase PPP1CA to prevents excessive phosphorylation of the translation initiation factor eIF-2A/EIF2S1, thereby reversing the shut-off of protein synthesis initiated by stress-inducible kinases and facilitating recovery of cells from stress.
No product in this corpus aims at PPP1R15A yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the roles drug-target, biomarker; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA PPP1R15A: RNA tissue enhanced (bone marrow 529 nTPM); blood lineage group enriched (dendritic cells 114 nTPM, granulocytes 335 nTPM); high antibody staining in 2 normal tissues; highest cancer staining endometrial cancer (3 of 12 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Colorectal cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas PPP1R15A tissue; Open Targets ENSG00000087074 associations
First described 1997. Earliest sequence paper UniProt cites for the protein: Hollander M.C. et al, J. Biol. Chem, 1997, "Mammalian GADD34, an apoptosis- and DNA damage-inducible gene". Source.
Sources: HGNC HGNC:14375 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O75807 (protein name, function text, keywords and locations (REST API)); CIViC gene PPP1R15A (1 evidence items, 0 assertions, 1 variants; diseases: Colorectal Cancer (GraphQL API, CC0))
Recruits the serine/threonine-protein phosphatase PPP1CA to prevents excessive phosphorylation of the translation initiation factor eIF-2A/EIF2S1, thereby reversing the shut-off of protein synthesis initiated by stress-inducible kinases and facilitating recovery of cells from stress. Down-regulates the TGF-beta signalling pathway by promoting dephosphorylation of TGFB1 by PP1. May promote apoptosis by inducing p53/TP53 phosphorylation on 'Ser-15'. Plays an essential role in autophagy by tuning translation during starvation, thus enabling lysosomal biogenesis and a sustained autophagic flux. Also acts a viral restriction factor by attenuating HIV-1 and influenza A virus replication. Mechanistically, mediates the inhibition of HIV-1 TAR RNA-mediated translation. Location: Endoplasmic reticulum membrane; Mitochondrion outer membrane (UniProt). Locus 19q13.2 (HGNC).
RNA: tissue enhanced (bone marrow 529 nTPM), detected in all normal tissues. Blood: group enriched (dendritic cells 114 nTPM, granulocytes 335 nTPM).
Medium: Appendix, Bone marrow, Breast, Bronchus, Cerebral cortex, Colon, Endometrium, Epididymis.
Medium only: carcinoid, head and neck cancer, liver cancer, lymphoma.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PPP1R15A" OR ABSTRACT:"PPP1R15A" OR TITLE:"protein phosphatase 1 regulatory subunit 15A" OR ABSTRACT:"protein phosphatase 1 regulatory subunit 15A" OR TITLE:"Protein phosphatase 1 regulatory subunit 15A" OR ABSTRACT:"Protein phosphatase 1 regulatory subunit 15A" OR TITLE:"GADD34" OR ABSTRACT:"GADD34") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PPP1R15A, not a curated reading list.